Reuters logo
BRIEF-AstraZeneca, Bristol resubmit dapagliflozin in U.S.
July 25, 2013 / 11:46 AM / in 4 years

BRIEF-AstraZeneca, Bristol resubmit dapagliflozin in U.S.

July 25 (Reuters) - AstraZeneca PLC : * Astrazeneca Plc and Bristol-Myers Squibb Co say resubmit

dapagliflozin new drug application in the U.S.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below